DNA-based mAbs (Inovio/AstraZeneca/Wistar Institute/University of Pennsylvania/Indiana University)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameDNA-based mAbs (Inovio/AstraZeneca/Wistar Institute/University of Pennsylvania/Indiana University)
Drug Alias NamedMAb-1dMAbdMAb-2
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionCoronavirus spike glycoprotein modulators
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesInovio Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesInovio Pharmaceuticals IncAstrazeneca PlcIndiana University +[5] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A